Therefore, it is essential to discover efficient antimicrobial methods that apply different mechanisms for the treatment of P. mirabilis could cause resistance to quinolones ( Dougnon et al., 2020 Santiago et al., 2020 Shaaban et al., 2022). Point mutations in gyrA, gyrB, and parC genes on chromosomes of P. Beta-lactam resistance was often found in MRPM due to the production of extended-spectrum beta-lactamases, AmpC enzymes, or metallo-beta-lactamases. mirabilis (MRPM), which is non-susceptible to at least one agent in three or more antimicrobial categories ( Magiorakos et al., 2012), has emerged in clinical treatment. In recent years, due to the intensive use of antibiotics, multi-drug resistant P. It can cause urethritis, bacteremia, pyelonephritis, otitis media, acute and chronic diarrhea in children, myelitis, diabetic foot infection, and other diseases ( Schaffer and Pearson, 2015 Palusiak, 2022). Proteus mirabilis is a Gram-negative bacterial opportunistic pathogen that belongs to the Morganellaceae family of the Enterobacterales order. These ornithine-porphyrin conjugates are potential photosensitizers for PACT in the treatment of MRPM infection. Photosensitizer 4d displayed high photo inactivation efficacy against MRPM at 7.81 μM under illumination, and it could accelerate wound healing via bactericidal effect. The PACT in vivo was evaluated using a wound mouse model infected by MRPM. Their photoinactivation efficacies against MRPM in vitro were reported and include the influence of laser energy, uptake, MIC and MBC, dose-dependent photoinactivation effects, membrane integrity, and fluorescence imaging. In this work, new cationic photosensitizers against multi-drug resistant Proteus mirabilis (MRPM) were designed and synthesized by the conjugation of amino phenyl porphyrin with basic amino acid L-ornithine. 3Center for Drug Evaluation, National Medical Products Administration, Beijing, Chinaįor the treatment of bacterial infections, photodynamic antimicrobial chemotherapy (PACT) has the advantage of circumventing multi-drug resistance.2Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.1Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China.Shuai Meng 1,2 † Zengping Xu 2,3 † Xueming Wang 2 Yang Liu 2 Bole Li 1 Jie Zhang 1 Xiaolong Zhang 1 Tianjun Liu 2 *
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |